Iberdomide vs ICP-490

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Iberdomide · Zenbexus

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomasmall molecule (CELMoD / cereblon E3 ligase modulator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT05560399 (registry estimate)

No aligned efficacy figure on record for this race.

ICP-490

Developed by Beijing InnoCare Pharma Tech Co.

Phase 1/2 in Multiple Myelomasmall molecule (cereblon-based molecular glue / IKZF1-3 degrader, CELMoD)
Weak signal

NCT05719701 · Phase 1/2 · status unknown

This is an unblinded, non-randomized dose-finding study with no control arm, and no results have been posted yet, so it cannot currently demonstrate a controlled treatment effect.

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIberdomideICP-490
PFS, median—Trial running · NCT04934475—Not reported
OS, median—Trial running · NCT04934475—Not reported
ORR—Trial running · NCT04934475—Not reported
VGPR or better—Trial running · NCT04934475—Not reported
MRD negativity—Trial running · NCT04934475—Not reported

PFS, median

Iberdomide
—Trial running · NCT04934475
ICP-490
—Not reported

OS, median

Iberdomide
—Trial running · NCT04934475
ICP-490
—Not reported

ORR

Iberdomide
—Trial running · NCT04934475
ICP-490
—Not reported

VGPR or better

Iberdomide
—Trial running · NCT04934475
ICP-490
—Not reported

MRD negativity

Iberdomide
—Trial running · NCT04934475
ICP-490
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Iberdomide: no structured comparison results are available for Multiple Myeloma.

ICP-490: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iberdomide's landscape · ICP-490's landscape